<DOC>
	<DOCNO>NCT01371760</DOCNO>
	<brief_summary>To assess double blind randomize control trial ( RCT ) study design safety effectiveness balloon angioplasty main extracranial extravertebral vein multiple sclerosis ( MS ) associate chronic cerebrospinal venous insufficiency ( CCSVI ) . Mean follow-up 1 year . 5-8 Italian centre 360 relapse remitting ( RR ) MS patient randomize , expand disability disease scale ( EDSS ) range 2-5.5 , age 18-65 .</brief_summary>
	<brief_title>BRAVE-DREAMS ( BRAin VEnous DRainage Exploited Against Multiple Sclerosis )</brief_title>
	<detailed_description>Safety assess measure serious minor adverse effect relate treatment . Effectiveness assess measure 2 primary endpoint : 1 . Clinical parameter express integrated functional measure lead score , respectively , improve , stable , worsen . Functional assessment perform tool permit quantification make team independent assessor . Clinical instrumental evaluation perform baseline , subsequently 3 month basis . The outcome parameter lead composite functional measure instrumental parameter , less assessor dependent , singularly validate measure disability MS . They following : A ) Dynamic Balance Assessment : Balance Master Limits Stability ( LOS ) . In static platform , swing reach set position center pressure . B ) Walking Function : The subject walk spontaneously 10 meter chronometric measure time count number step . The test calculate walk ratio i.e . ratio length step frequency . C ) Manual dexterity . Box &amp; Block test , move wooden cube . D ) Sphincter control : Post-voiding residual ultrasound . F ) Visual acuity : Low-contrast visual acuity Sloan Letter Chart . 2 . Magnetic Resonance Imaging ( MRI ) outcome measure : T1Gad active lesion.T2 lesion volume MRI evaluation baseline , 6 , 12 month . Secondary endpoint : EDSS , chronic fatigue , cognitive function , rate restenosis , annualized relapse rate .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Venous Insufficiency</mesh_term>
	<criteria>patient affect CCSVI associate MS relapsingremitting and\or secondary progressive 1865 year old EDSS 25 disease duration &lt; 10y No relapse 30 day precede procedure clinical stability last 6 month disease mod . treatment Patients best available therapy patient previously treat CCSVI inserted clinical trial last 3 month treatment natalizumab pregnant refuse adopt contraception presence significant comorbidities alcooldrug abuse thrombophilia contraindication MR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Chronic cerebrospinal venous insufficiency</keyword>
	<keyword>Percutaneous Transluminal Angioplasty ( PTA )</keyword>
	<keyword>Internal jugular vein</keyword>
	<keyword>Azygous vein</keyword>
</DOC>